US Appeals Court Clears Way for Generic Omega-3 Pills

Jacob Harper |

Reversing an earlier US district court decision on Sept. 12, a US appeals court ruled both Teva Pharmaceutical Industries Ltd. (TEVA) and Par Pharmaceuticals could go ahead with plans to market a generic version of GlaxoSmithKline plc (GSK) subsidiary Pronova's blockbuster omega-3 drug Lovaza. Small-cap Irish biopharma Amarin plc (AMRN) , whose only product is a competitor to Lovaza, was rocked by the court’s decision to allow additional competition from generics.

In their ruling, the US appeals court found that Lovaza was made “publicly accessible before the statutory bar date” and that since the patent for Lovaza had expired in March 2013, it was no longer protected from generics.

Lovaza, which contains high doses of omega-3s in the form of, esterified fish oils, has been a smash for GlaxoSmithKline, racking up $2.3 billion in US sales by Aug. 2010.

Amarin had put everything into competing with Lovaza with their sole product, Vascepa. A synthetic derivative of fish oil, had been shown to be even more effective than Lovaza in treating patients with high trigycerides, and finally won FDA approval in July 2012. However, Amarin had chosen to forgo taking on a partner in marketing and distributing the drug, slowing down its march to market.

Even though Vascepa is an effective alternative to Lovaza, with generics now expected to flood the market, it will be much more difficult for Amarin to market their drug.

The giant GlaxoSmithKline was relatively unfazed by the ruling. However, Amarin dropped 5.86 percent on the news to hit $6.75 a share amid four times normal volume.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
GSK GlaxoSmithKline PLC 37.70 0.27 0.72 3,910,786
AMRN Amarin Corporation plc 3.17 0.09 2.92 1,206,100
TEVA Teva Pharmaceutical Industries Limited American De 36.53 -0.04 -0.11 6,924,116
CVALF Covalon Techs Ltd 1.24 -0.05 -4.21 3,500

Comments

Emerging Growth

Lomiko Metals Inc.

Lomiko Metals Inc is an exploration stage company. It is engaged in the acquisition, exploration and development of resource properties. Its projects include Vines Lake project and Quatre - Milles…

Private Markets

8tracks

Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.

Dropbox, Inc.

Dropbox is a service that allows their users to bring all photos, docs, and videos anywhere, and share them easily. Any file saved to Dropbox will automatically save to all…